Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Smit

Showing results (291-300 of 692) with videos related to

Pageof 70
Sort By:
Lung Cancer (Amsterdam, Netherlands)|May 24, 2014
Metabolic activity measured by FDG PET predicts pathological response in locally advanced superior sulcus NSCLCI Bahce, C G Vos, C Dickhoff, et al.
Acta Psychiatrica Scandinavica|October 15, 2009
Identifying target groups for the prevention of anxiety disorders in the general populationN M Batelaan, F Smit, R de Graaf, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007
Genetic heterogeneity in patients with multiple neoplastic lung lesions: a report of three casesMariëlle I Gallegos Ruiz, Hester van Cruijsen, Egbert F Smit, et al.
European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery|July 21, 2009
Evaluation of a treatment strategy for optimising preoperative chemoradiotherapy in stage III non-small-cell lung cancerErik C J Phernambucq, Femke O B Spoelstra, Marinus A Paul, et al.
The British Journal of Nutrition|November 17, 2012
Pre-cachexia and cachexia at diagnosis of stage III non-small-cell lung carcinoma: an exploratory study comparing two consensus-based frameworksBarbara S van der Meij, Coline P Schoonbeek, Egbert F Smit, et al.
Lung Cancer (Amsterdam, Netherlands)|October 1, 2018
Crizotinib treatment for patients with EGFR mutation positive NSCLC that acquire cMET amplification after EGFR TKI therapy results in short-lived and heterogeneous responsesBianca van Veggel, Adrianus J de Langen, Sayed Hashemi, et al.
Molecular Oncology|March 16, 2017
A genome-wide siRNA screen for regulators of tumor suppressor p53 activity in human non-small cell lung cancer cells identifies components of the RNA splicing machinery as targets for anticancer treatmentEllen Siebring-van Olst, Maxime Blijlevens, Renee X de Menezes, et al.
British Journal of Cancer|December 15, 2004
A randomised phase II trial of docetaxel vs docetaxel and irinotecan in patients with stage IIIb-IV non-small-cell lung cancer who failed first-line treatmentF M Wachters, H J M Groen, B Biesma, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2005
The natural course of preneoplastic lesions in bronchial epitheliumRoderick H Breuer, Arifa Pasic, Egbert F Smit, et al.
Cancers|July 2, 2021
Response Prediction and Evaluation Using PET in Patients with Solid Tumors Treated with ImmunotherapyFrank J Borm, Jasper Smit, Daniela E Oprea-Lager, et al.
Pageof 70

Showing results (291-300 of 692) with videos related to

Sort By:
Pageof 70
Lung Cancer (Amsterdam, Netherlands)|May 24, 2014
Metabolic activity measured by FDG PET predicts pathological response in locally advanced superior sulcus NSCLCI Bahce, C G Vos, C Dickhoff, et al.
Acta Psychiatrica Scandinavica|October 15, 2009
Identifying target groups for the prevention of anxiety disorders in the general populationN M Batelaan, F Smit, R de Graaf, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007
Genetic heterogeneity in patients with multiple neoplastic lung lesions: a report of three casesMariëlle I Gallegos Ruiz, Hester van Cruijsen, Egbert F Smit, et al.
European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery|July 21, 2009
Evaluation of a treatment strategy for optimising preoperative chemoradiotherapy in stage III non-small-cell lung cancerErik C J Phernambucq, Femke O B Spoelstra, Marinus A Paul, et al.
The British Journal of Nutrition|November 17, 2012
Pre-cachexia and cachexia at diagnosis of stage III non-small-cell lung carcinoma: an exploratory study comparing two consensus-based frameworksBarbara S van der Meij, Coline P Schoonbeek, Egbert F Smit, et al.
Lung Cancer (Amsterdam, Netherlands)|October 1, 2018
Crizotinib treatment for patients with EGFR mutation positive NSCLC that acquire cMET amplification after EGFR TKI therapy results in short-lived and heterogeneous responsesBianca van Veggel, Adrianus J de Langen, Sayed Hashemi, et al.
Molecular Oncology|March 16, 2017
A genome-wide siRNA screen for regulators of tumor suppressor p53 activity in human non-small cell lung cancer cells identifies components of the RNA splicing machinery as targets for anticancer treatmentEllen Siebring-van Olst, Maxime Blijlevens, Renee X de Menezes, et al.
British Journal of Cancer|December 15, 2004
A randomised phase II trial of docetaxel vs docetaxel and irinotecan in patients with stage IIIb-IV non-small-cell lung cancer who failed first-line treatmentF M Wachters, H J M Groen, B Biesma, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2005
The natural course of preneoplastic lesions in bronchial epitheliumRoderick H Breuer, Arifa Pasic, Egbert F Smit, et al.
Cancers|July 2, 2021
Response Prediction and Evaluation Using PET in Patients with Solid Tumors Treated with ImmunotherapyFrank J Borm, Jasper Smit, Daniela E Oprea-Lager, et al.
Pageof 70